For example, as a kind of thyroid hormone receptor beta agonist, resmetirom has been proven to have the effect of reducing liver lipids.[3, 4] Besides, GLP‐1 receptor agonist and FGF21 analogs have become the forefront research directions in the MASLD treatment.[5, 6] Despite significant progress of endocrine hormones as therapeutic targets, the treatment results are not entirely satisfactory as the pathogenesis of MASLD is complex and in‐depth understanding of its mechanisms is still limited. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.